MIF4GD

Across TCGA pan-cancer cohorts, MIF4GD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MIF4GD data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MIF4GD mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MIF4GD expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where MIF4GD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.202	0.985	.007	18	view →
PDAC	OS	Tertile	III,IV	0.686	0.340	.014	8	view →
LSCC	DFS	Quartile	II,III,IV	0.788	1.000	.004	6	view →
GBM	OS	Median	All	0.288	0.449	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MIF4GD–CCRCC (OS)

Open the CCRCC breakdown →